A view of the JLK booth installed at ISC 2024 held at the Phoenix Convention Center in the United States last February. Provided by JLK
JLKE is taking steps to establish a foothold for full-scale entry into overseas medical institutions.
Stroke AI specialist JLKE (CEO Dongmin Kim) announced that it will participate in the 2025 International Stroke Conference (ISC 2025), held from February 5 to 7 next year at the Los Angeles Convention Center in the United States, showcasing an interactive booth for visitors and presenting research abstracts on its solutions, launching an all-out effort to enter the U.S. market.
ISC 2025 is an academic event jointly hosted by the American Heart Association and the Stroke Association, recognized as the most prestigious international event where global stroke scholars and clinical experts gather to discuss research results with the goal of brain health through the development of stroke treatment technologies.
From the first day, JLKE plans to attract the attention of global medical institution officials with a unique exclusive booth. At the center of the booth, a triangular prism-shaped JLKE solution experience zone will be set up, providing an engaging experience where medical staff can view actual stroke patient imaging data, predict prognosis, and then compare their predictions with the results provided by artificial intelligence. JLKE’s strategy is to naturally draw the interest of global medical professionals through this interactive content.
On the second day, a special session will showcase the convenience and technological capabilities of JLKE’s AI solution confirmed in clinical settings. This session will feature a research abstract presentation titled “Improving Detection Sensitivity of High-Difficulty Acute Cerebral Infarction Lesions on Diffusion-Weighted Imaging (DWI) Using JLKE Artificial Intelligence Solution JBS-01K (JLK-DWI).”
JLKE CEO Dongmin Kim stated, “ISC is an event attended by about 5,500 global medical institution officials and stroke experts, providing a valuable opportunity to showcase JLKE’s technological capabilities to overseas researchers and stroke scholars,” adding, “Through this event, we will further expand JLKE’s presence in the global medical market.”
In particular, CEO Kim added, “The stroke full solution ‘MediHub Stroke,’ which JLKE is intensively promoting, is a bundled platform combining multiple AI solutions developed according to international standards,” and “We plan to make every effort through this ISC to enable more global medical institutions to adopt JLKE’s solutions.”
Meanwhile, ISC 2025 will also feature participants such as Israel’s Viz.ai and the U.S.’s Rapid AI, recognized as leading companies in the global AI stroke field, setting the stage for fierce competition surrounding stroke AI technologies.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
